2026-06-30T02:51:34Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/69912025-05-07T12:33:26Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Kovar, Heinrich author Alonso, Javier author Aman, Pierre author Aryee, Dave N T author Ban, Jozef author Burchill, Sue A author Burdach, Stefan author de Álava, Enrique author Delattre, Olivier author Dirksen, Uta author Fourtouna, Argyro author Fulda, Simone author Helman, Lee J author Herrero-Martin, David author Hogendoorn, Pancras C W author Kontny, Udo author Lawlor, Elizabeth R author Lessnick, Stephen L author Llombart-Bosch, Antonio author Metzler, Markus author Moriggl, Richard author Niedan, Stephan author Potratz, Jenny author Rédini, Françoise author Richter, Günther H S author Riedmann, Lucia T author Rossig, Claudia author Schäfer, Beat W author Schwentner, Raphaela author Scotlandi, Katia author Sorensen, Poul H author Staege, Martin S author Tirode, Franck author Toretsky, Jeffrey author Ventura, Selena author Eggert, Angelika author Ladenstein, Ruth author 2012-05 The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20%. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials. Front Oncol. 2012;2:54 10.3389/fonc.2012.00054 2234-943X 2234-943X Frontiers in oncology 22662320 http://hdl.handle.net/20.500.12105/6991 Ewing sarcoma Animal models Biomarkers Drug screen Epigenetics Genomics Prognosis Sarcomagenesis The first European interdisciplinary ewing sarcoma research summit